Latest News
Axsome Therapeutics, Inc.
- Axsome Therapeutics Needs Auvelity Growth To Outrun Launch Costs (NASDAQ:AXSM)
- Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
- Mizuho reiterates Outperform on Axsome stock ahead of earnings
- RBC Capital reiterates Axsome Therapeutics stock rating at Outperform
- Axsome Therapeutics Stock: 12 Straight Red Days, Down 15%
- Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?
- Axsome Therapeutics Stock Extends An 11-Day Losing Streak To A 14% Loss
- 10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13%
- Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days
- Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
- Wells Fargo Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
- Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst
Headlines from the last 30 days, linking to the original publishers. See all market news →